Loading clinical trials...
Loading clinical trials...
A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Conditions
Interventions
gene-modified T cells targeted
Locations
1
United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
January 5, 2010
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2027
Last Updated
April 27, 2026
NCT06735690
NCT05564390
NCT00131014
NCT03050268
NCT06074666
NCT06846671
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions